To the Editor Phillips et al1 have reported a phase 2 randomized clinical trial assessing the role of stereotactic body radiotherapy in men with up to 3 nodal and/or bone metastases after primary treatment for prostate cancer. The authors should be commended for this trial, which showed higher efficacy of metastasis-directed therapy (MDT) without concomitant systemic treatment compared with observation with regard to 6-month progression-free survival. However, unfortunately, this trial fails to shed light on the correct management of oligorecurrent prostate cancer for the following reasons.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Briganti A, Gandaglia G, Montorsi F. Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer—Not All That Glitters Is Gold. JAMA Oncol. 2020;6(10):1638–1639. doi:10.1001/jamaoncol.2020.2829
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: